StockWatch
·
Personal Care
Quarterly Result13 Nov 2026, 01:02 pm

Gillette India Q2 FY27 (standalone): PAT +10.8% YoY to ₹159 Cr, oral care margins sink

AI Summary

Gillette India's standalone Q2 FY27 revenue rose 4.35% YoY to ₹846.10 Cr (₹810.81 Cr a year ago) and 8.06% QoQ from ₹783.02 Cr, with net profit up 10.76% YoY to ₹159.10 Cr (₹143.65 Cr YoY) but essentially flat QoQ (-0.22%) against ₹159.45 Cr last quarter. EPS came in at ₹48.83 versus ₹44.08 a year ago. No exceptional or one-off items appear in either period, so these are straight reported growth numbers. Against the pre-result preview we published, revenue beat the ₹800-820 Cr expected band by about 3%, but PAT (₹159.10 Cr) missed the ₹162-170 Cr expected band — a beat-on-top-line, miss-on-bottom-line split. Net profit margin expanded 109 bps YoY to 18.62% (17.53% a year ago) and operating margin expanded 125 bps YoY to 26.87% (25.62%), but both compressed sequentially — NPM down 160 bps and OPM down 222 bps from Q1 FY27's 20.23%/29.09%. The segment split explains the divergence. Grooming revenue (₹679.00 Cr, +1.96% YoY, inside the preview's ₹665-685 Cr range) grew segment PBIT 18.5% YoY and 10.9% QoQ to ₹192.43 Cr, with segment margin expanding to 28.3% from 24.4% a year ago, aided by cost of materials consumed falling to 19.6% of revenue from 30.6% YoY. Oral Care revenue grew faster, +15.34% YoY and +8.25% QoQ to ₹167.10 Cr — beating the preview's ₹145-155 Cr range — but its segment PBIT fell 31.8% YoY and 53.6% QoQ to ₹17.48 Cr, with segment margin collapsing to 10.5% from 17.7% YoY and 24.4% last quarter. Revenue growth leaned increasingly on purchased/traded goods rather than own manufacturing — purchases of stock-in-trade rose to 24.9% of revenue from 14.1% YoY — a mix shift that likely carries a thinner margin and shows up directly in Oral Care's profit squeeze even as its topline outperformed. Gillette India does not publish formal forward guidance, so there is no prior company outlook to grade this print against. No standalone management press-release commentary was available to quote alongside the filing. On corporate developments, the quarter saw a new Executive Director appointed to the board, LIC disclosing a 2.01% stake reduction, the 42nd AGM and FY26 annual report, and the standard trading-window closure (Sep 28-Nov 13) ahead of this result — none of which shows a direct read-through in the segment numbers. We found no separate third-party brokerage consensus for this specific quarter beyond our own pre-result preview, which flagged the Street's 15-20% full-year FY27 PAT growth expectation; this quarter's 10.76% YoY PAT growth trails that pace. The quarter leaves two open threads for Q3 FY27: whether Oral Care's margin — more than halved sequentially to 10.5% — recovers as its revenue growth continues, and whether the raw-material cost tailwind behind Grooming's margin gains persists as the business leans more on traded/imported goods (now a quarter of revenue, up from 14.1% a year ago).

Key Highlights

  • Revenue ₹846.10 Cr, +4.35% YoY / +8.06% QoQ — Grooming ₹679.00 Cr (+1.96% YoY, within preview's ₹665-685 Cr range), Oral Care ₹167.10 Cr (+15.34% YoY, beat preview's ₹145-155 Cr range)
  • Standalone PAT ₹159.10 Cr, +10.76% YoY (flat QoQ, -0.22%); EPS ₹48.83 vs ₹44.08 YoY — missed our pre-result preview's ₹162-170 Cr PAT band
  • NPM 18.62% (+109bps YoY, -160bps QoQ) and OPM 26.87% (+125bps YoY, -222bps QoQ) — YoY expansion, QoQ compression
  • Oral Care segment PBIT ₹17.48 Cr, down 31.8% YoY / 53.6% QoQ despite revenue growth — segment margin fell to 10.5% from 17.7% YoY and 24.4% QoQ
  • Grooming segment PBIT ₹192.43 Cr, up 18.5% YoY / 10.9% QoQ — segment margin expanded to 28.3% from 24.4% YoY as materials cost fell to 19.6% of revenue (30.6% YoY)
  • Mix shift toward traded/imported goods — purchases of stock-in-trade rose to 24.9% of revenue from 14.1% YoY, as own-manufactured material cost share fell
  • Corporate developments this quarter: new Executive Director appointed to the board; LIC disclosed a 2.01% stake reduction; 42nd AGM/FY26 annual report; trading window closed Sep 28-Nov 13 around this result